Login to Your Account


RARE DISEASE DAY 2017

As the industry recognizes Rare Disease Day Tuesday, there's plenty to celebrate. The acquisition of Baxalta Inc. by Shire plc early in 2016 created a global giant with an equally large appetite for therapies to treat rare indications.

more »


Analysis

Myovant Sciences Inc.'s kickoff to 2017 with a phase III trial testing its oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix in uterine fibroids (UFs) signaled a year of tighter focus on the condition, with a group of heavyweight drug developers involved in that indication as well as endometriosis.

read more »

Opinion


Partners in Focus